Open Orphan (ORPH)

Sector:

Health Care

Index:

FTSE AIM All-Share

5.88p
   
  • Change Today:
    -0.15p
  • 52 Week High: 8.00
  • 52 Week Low: 2.55
  • Currency: UK Pounds
  • Shares Issued: 533.05m
  • Volume: 1,045,207
  • Market Cap: £31.32m
  • RiskGrade: 271

Open Orphan signs deal with US biopharmaceutical firm SFA

By Josh White

Date: Wednesday 18 Dec 2019

LONDON (ShareCast) - (Sharecast News) - Europe-focussed rare and orphan drug consulting service provider Open Orphan announced the signing of a contract with SFA Therapeutics, a biopharmaceutical company based in Pennsylvania, on Wednesday.
The AIM-traded firm said the contract would see Venn Life Sciences, part of Open Orphan, provide SFA Therapeutics with assistance in the filing of a European Medicines Agency application for Orphan Drug Designation, including providing both consulting and regulatory writing services.

Open Orphan said it was "delighted" to support SFA Therapeutics in the development of its promising novel treatment, adding that it hoped the agreement would be the first step in a longer-term relationship between both companies.

The board said the contract was evidence of Open Orphan executing its strategy of winning contracts in the fast-growing orphan drug sector, and its capability in being able to assist North American companies with their European activities.

It added that it was also an important contract due to the fact it was the first time that Venn had used Open Orphan's skills and expertise in filing a European Medicines Agency Orphan Drug Designation for a North American company, which already has a US FDA Orphan Drug Designation.

"This contract is a further demonstration of delivery against one of Open Orphan's key objectives, transforming Venn," said chief executive officer Cathal Friel.

"The contract is an exciting one as we are now building on our capability by actively winning work in the fast-growing orphan drug sector.

"We look forward to delivering the contract for SFA Therapeutics and building upon the relationship."

At 1214 GMT, shares in Open Orphan were up 2.65% at 5.8p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Open Orphan Market Data

Currency UK Pounds
Share Price 5.88p
Change Today -0.15p
% Change -2.49 %
52 Week High 8.00
52 Week Low 2.55
Volume 1,045,207
Shares Issued 533.05m
Market Cap £31.32m
RiskGrade 271

Open Orphan Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
12.76% above the market average12.76% above the market average12.76% above the market average12.76% above the market average12.76% above the market average
2.44% below the sector average2.44% below the sector average2.44% below the sector average2.44% below the sector average2.44% below the sector average
Income Not Available
Growth
38.93% below the market average38.93% below the market average38.93% below the market average38.93% below the market average38.93% below the market average
48.57% below the sector average48.57% below the sector average48.57% below the sector average48.57% below the sector average48.57% below the sector average

Open Orphan Dividends

No dividends found

Trades for 25-Feb-2020

Time Volume / Share Price
16:29 156,426 @ 5.85p
16:28 4,898 @ 5.88p
15:17 84,578 @ 5.90p
14:32 50,000 @ 5.87p
14:15 100,000 @ 5.88p

Open Orphan Key Personnel

CEO Trevor Phillips
COO Tim Sharpington
CFO Leo Toole

Top of Page